Results 131 to 140 of about 87,925 (315)

Age and dPCR can predict relapse in CML patients who discontinued imatinib: The ISAV study

American journal of hematology/oncology, 2015
Imatinib is effective for the treatment of chronic myeloid leukemia (CML). However even undetectable BCR‐ABL1 by Q‐RT‐PCR does not equate to eradication of the disease.
S. Mori, Elisabetta Vagge, P. le Coutre, E. Abruzzese, B. Martino, E. Pungolino, C. Elena, I. Pierri, S. Assouline, A. D'emilio, A. Gozzini, P. Giraldo, F. Stagno, A. Iurlo, M. Luciani, Giulia De Riso, S. Redaelli, Dong-Wook Kim, A. Pirola, C. Mezzatesta, A. Petroccione, Agnese Lodolo D'Oria, P. Crivori, R. Piazza, C. Gambacorti-Passerini   +24 more
semanticscholar   +1 more source

Ponatinib‐related gelatinous transformation of the bone marrow

eJHaem, EarlyView.
Stefano Lazzi, Brunangelo Falini
wiley   +1 more source

Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

Andrology, EarlyView.
Abstract Background Growing evidence indicates that paternal condition significantly influences pregnancy outcomes and offspring health. However, assessing the safety of paternal drug exposure via randomized controlled trials poses ethical challenges, and relevant clinical studies consume a lot of resources to evaluate only a few drugs.
Yanbin Zeng, Wanlong Lin, Wei Zhuang
wiley   +1 more source

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Haematologica, 2015
We have previously reported on the efficacy and tolerability of hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and imatinib followed by imatinib-based consolidation/maintenance therapy in 20 patients with newly ...
N. Daver, Deborah M. Thomas, F. Ravandi, J. Cortes, Rebecca E. Garris, E. Jabbour, G. Garcia-Manero, G. Borthakur, T. Kadia, M. Rytting, M. Konopleva, H. Kantarjian, S. O'brien   +12 more
semanticscholar   +1 more source

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

Mediterranean Journal of Hematology and Infectious Diseases, 2013
Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid leukemia (CML).
Tomasz Sacha
doaj   +1 more source

Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta [PDF]

, 2002
Jane F. Apperley, Martine Gardembas, Junia V. Melo, R. Russell‐Jones, Barbara J. Bain, E. Joanna Baxter, Andrew Chase, Judith M. Chessells, Marie Colombat, Claire Dearden, Saša Dimitrijević, François-X. Mahon, David Marin, Zariana Nikolova, Eduardo Olavarría, Sandra Silberman, Beate Schultheis, Nicholas C.P. Cross, John M. Goldman   +18 more
openalex   +1 more source

A critical review of management of allogeneic transplant‐eligible adults with Ph+ acute lymphoblastic leukaemia

British Journal of Haematology, EarlyView.
Proposed management of newly diagnosed Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukaemia (ALL) in transplant‐eligible patients. Suggested considerations when deciding the treatment pathway available to a newly diagnosed Ph+ ALL patient that would be deemed transplant eligible. Summary Acute lymphoblastic leukaemia (ALL) in 20%–30% of
Naranie Shanmuganathan, Andrew Grigg
wiley   +1 more source

Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

Haematologica, 2008
Treatment with imatinib is very effective in Bcr-Abl positive leukemia. However, development of resistance to this drug is a common phenomenon in late stage disease.
Rama Krishna Kancha, Nikolas von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S. Götze, Justus Duyster   +5 more
doaj   +1 more source

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias [PDF]

, 2002
Oliver G. Ottmann, Brian J. Druker, Charles L. Sawyers, John M. Goldman, J Reiffers, Richard T. Silver, S Tura, Thomas Fischer, Michael W. Deininger, Charles A. Schiffer, Michele Baccarani, Aloïs Gratwohl, Andreas Hochhaus, Dieter Hoelzer, Sofia Fernandes‐Reese, Insa Gathmann, Renaud Capdeville, Stephen G. O’Brien   +17 more
openalex   +1 more source

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting

British Journal of Haematology, EarlyView.
Therapeutic drug monitoring (TDM) of imatinib is reported from a real‐world study in 66 children with paediatric Chronic Myeloid Leukemia (pCML). TDM allows dose adjustments, improving molecular response rates and is a step forward in personalized pCML care.
Meinolf Suttorp, Stephanie Sembill, Phyllis Lensker, Verena Hildebrand, Elke Schirmer, Axel Karow, Manuela Krumbholz, Manfred Rauh, Markus Metzler   +8 more
wiley   +1 more source